Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2017 | What are the practical considerations for monoclonal antibody infusion?

Torben Plesner, MD, from the Vejle Hospital and University of Southern Denmark, Vejle, Denmark, discusses practical management of monoclonal antibody infusion at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He explains that for the monoclonal antibody daratumumab, few infusion side effects are seen, and explains what should be done if nasal congestion is observed during the infusion and when the infusion can be resumed. Prof. Plesner gives an overview of the expected infusion times for the first infusion and subsequent infusions, and mentions a new subcutaneous formulation of daratumumab which is being developed.